

3 November 2025

TEDD Visit

**Research & Education at
University Children's Hospital
Zurich (KISPI)**

Zurich, Switzerland

Program

09:30 - 10:00	Arrival: Coffee & Gipfeli
10:00 - 10:10	Welcome and Introduction of TEDD Dr. Markus Rimann
10:10 - 10:25	Welcome and introduction of KISPI Prof. Dr. med. Matthias Baumgartner Prof. Javad Nazarian
10:25 - 10:50	Modelling drug response in pediatric diffuse midline glioma from multi-omics characterization Prof. Sarah C. Brüningk
10:50 - 11:00	Break
11:00 - 11:25	Engineering and controlling biohybrid and biomimetic microrobots for magnetically enhanced drug delivery Prof. Simone Schürle-Finke
11:25 - 11:45	Recapitulating the BBB in vitro to test drug penetration and efficacy Dr. Mario M. Modena
11:45 - 12:05	Ultrasound-Triggered Drug Release Dynamics for Neural Circuit Manipulation Dr. Gizem Aydemir
12:05 - 12:25	Closing Remarks, Q&A, Group Photo Dr. Markus Rimann Prof. Javad Nazarian
12:50 - 13:30	Lunch
13:30 - 15:00	Tour of the KISPI Research building

About



[Event Website](#)

At the University Children's Hospital Zurich (KISPI), the fight against childhood cancer brings together some of the most dedicated doctors and researchers in Europe. Within the hospital's Oncology Department, young patients and their families receive care that combines the latest scientific advances with compassion and support. Teams of pediatric oncologists, neurosurgeons, nurses, and psychologists work side by side, ensuring that every child facing cancer is treated not only with medicines and therapies, but also with understanding and hope.

Among the many conditions treated at KISPI, a particular focus is placed on brain tumors such as diffuse midline glioma (DMG), also known as DIPG. These tumors are among the most challenging in pediatric oncology, and for decades little progress had been made in improving outcomes. To change this reality, KISPI established a dedicated DIPG/DMG Center of Expertise. One of the most promising initiatives led from Zurich is called DMG-ACT, which stands for Diffuse Midline Glioma – Adaptive Combinatorial Therapy. This international effort, driven by collaboration across many hospitals and research teams worldwide, aims to give children diagnosed with DMG access to innovative therapies much faster. A key part of KISPI research is drug screening, where relevant medicines are tested against tumor cells to identify promising candidates. Equally important, is the development of advanced cell cultures, miniature tumor models grown in the laboratory, which allow researchers to study how these cancers behave and to predict how children might respond to new treatments.

The hope is simple but powerful: that by working together, and by investing in science as much as in care, we can finally change the story for children and families facing this devastating disease.

Organisers



Prof Javad Nazarian
javad.nazarian@kispi.uzh.ch



Sandra Laternser
sandra.laternser@kispi.uzh.ch



Dr Markus Rimann
markus.rimann@zhaw.ch



Dr Katarzyna Kopanska
katarzyna.kopanska@zhaw.ch

Information

TEDD Partners have priority of registration.

Cost

TEDD Partners (two participants)

3rd and next TEDD Partner

KISPI Oncology

Others

No entrance fee

CHF 40

No entrance fee


CHF 80

Registration

27 October 2025



[Link to register](#)



Contact

Katarzyna Kopanska

katarzyna.kopanska@zhaw.ch


Location

(A) Forschung & Lehre
Universitäts-Kinderspital Zürich
Auditorium B, ground level
August-Forel-Strasse 51
8008 Zürich



(B) Public Transport
Tram 11 to Balgrist
Bus 77 to Flühgasse
Bus 99 to Kinderspital
Forchbahn (S18) to Balgrist

(C) Car Park
A limited number of parking spaces are available in the underground garage of the akutspital (entrance via Lenggstrasse), public transport is generally thus suggested.





About TEDD Competence Centre

TEDD (Tissue Engineering for Drug Development and Substance Testing) is an education, R&D and networking platform promoting the application of 3D organotypic technologies, with the core goal of replacing animal experimentation for therapies development.

Based in Switzerland, TEDD is focused on 3D for 3Rs. The community is composed of international members from academia, clinics, industry and non-profits.

Training of members is achieved through regular events at the national and international level, including workshops, symposia, company visits, scientific reviews and we provide a platform to generate research consortia, projects and grant applications.



[TEDD Website](#)



[Follow TEDD](#)